vancomycin has been researched along with lff571 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaral, A; Brewer, JT; Bushell, SM; Deng, G; Dewhurst, JM; Ding, J; Dzink-Fox, J; Gamber, G; Jain, A; LaMarche, MJ; Lee, K; Lee, L; Leeds, JA; Lister, T; McKenney, D; Mullin, S; Osborne, C; Palestrant, D; Patane, MA; Rann, EM; Sachdeva, M; Shao, J; Tiamfook, S; Trzasko, A; Whitehead, L; Yan, W; Yifru, A; Yu, D; Zhu, Q | 1 |
| Lamarche, MJ; Leeds, JA; McKenney, D; Praestgaard, J; Trzasko, A | 1 |
| Bauer, MP; Debast, SB; Kuijper, EJ; Sanders, IM; Wilcox, MH | 1 |
| Barnes, SW; Leeds, JA; Mullin, S; Ruzin, A; Sachdeva, M | 1 |
| Leeds, JA; Sachdeva, M | 1 |
| Bhansali, SG; Dabovic, K; Leeds, JA; Mullane, K; Pertel, P; Praestgaard, J; Ting, LS | 1 |
| Blais, J; Bressler, A; Buitrago, M; Dabovic, K; Lee, C; Leeds, JA; Mullane, K; Pertel, P; Praestgaard, J; Weiss, K | 1 |
2 trial(s) available for vancomycin and lff571
| Article | Year |
|---|---|
Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Feces; Female; Humans; Male; Middle Aged; Thiazoles; Vancomycin | 2015 |
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Female; Humans; Male; Middle Aged; Thiazoles; Vancomycin | 2015 |
5 other study(ies) available for vancomycin and lff571
| Article | Year |
|---|---|
Discovery of LFF571: an investigational agent for Clostridium difficile infection.
Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Cricetinae; Crystallography, X-Ray; Enterococcus; Enterocolitis, Pseudomembranous; Escherichia coli Proteins; Female; Male; Mesocricetus; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Peptide Elongation Factor Tu; Rats; Rats, Sprague-Dawley; Solubility; Staphylococcus aureus; Streptococcus pyogenes; Structure-Activity Relationship; Thiazoles; Water | 2012 |
Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Cricetinae; Enterocolitis, Pseudomembranous; Enterotoxins; Male; Mesocricetus; Recurrence; Thiazoles; Vancomycin | 2012 |
Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infection; Enterocolitis, Pseudomembranous; Europe; Fidaxomicin; Humans; Metronidazole; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymerase Chain Reaction; Ribotyping; Thiazoles; Treatment Outcome; Vancomycin | 2013 |
In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cell Wall; Clostridioides difficile; DNA Mutational Analysis; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Fidaxomicin; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Selection, Genetic; Sequence Analysis, DNA; Serial Passage; Thiazoles; Vancomycin | 2014 |
Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
Topics: Aminoglycosides; Clostridioides difficile; Fidaxomicin; Metronidazole; Microbial Sensitivity Tests; Thiazoles; Vancomycin | 2015 |